8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Mar 4, 2026·SEC
Keros Therapeutics, Inc.(KROS)Earnings, Financials & Key Ratios
KROS•NASDAQ
4.6× P/E·Price updated Jun 19, 2026
AboutKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$244M+6775.0%
- EBITDA$72M+134.4%
- Net Income$87M+146.4%
- EPS (Diluted)2.30+146.0%
- Gross Margin99.38%-0.6%
- EBITDA Margin29.55%+100.5%
- Operating Margin28.94%+100.5%
- Net Margin35.65%+100.7%
- ROE19.9%+148.0%
KROS Key Insights
Keros Therapeutics, Inc. (KROS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 43.4% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 16 (bottom 16%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KROS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KROS Price & Volume
Keros Therapeutics, Inc. (KROS) stock price & volume — 10-year historical chart
Loading chart...
KROS Growth Metrics
Keros Therapeutics, Inc. (KROS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-84.55%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2121.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-712.5%
Return on Capital
10 Years-35.99%
5 Years-29.66%
3 Years-27.67%
Last Year15.59%
KROS Recent Earnings
Keros Therapeutics, Inc. (KROS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (43%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$1.21-31.5%
$0.92
Rev
$367,000-81.0%
$2M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.86-75.5%
$0.49
Rev
$385,000-89.5%
$4M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.18+83.8%
$1.11
Rev
$14M+289.4%
$4M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.76+33.3%
$1.14
Rev
$18M+465.9%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $1.21vs $0.92-31.5% | $367,000vs $2M-81.0% |
| Q2 2026 | Mar 4, 2026 | $0.86vs $0.49-75.5% | $385,000vs $4M-89.5% |
| Q4 2025 | Nov 5, 2025 | $0.18vs $1.11+83.8% | $14Mvs $4M+289.4% |
| Q3 2025 | Aug 6, 2025 | $0.76vs $1.14+33.3% | $18Mvs $3M+465.9% |
Based on last 12 quarters of dataView full earnings history →
KROS Peer Comparison
Keros Therapeutics, Inc. (KROS) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 SMMT | 10.66B | 13.75 | -9.55 | -340.55% | 0.03 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare KROS vs Peers
Keros Therapeutics, Inc. (KROS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KROS Income Statement
Keros Therapeutics, Inc. (KROS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 10M | 10M | 0 | 20.1M | 0 | 151K | 3.55M | 244.06M | 33.18M |
Revenue Growth % | - | 0% | -100% | - | -100% | - | 2250.99% | 6774.96% | -84.55% |
Cost of Goods Sold | 10.11M | 17.35M | 605K | 0 | 0 | 0 | 0 | 1.51M | 1.17M |
COGS % of Revenue | 101.11% | 173.48% | - | - | - | - | - | 0.62% | - |
Gross Profit | -111K▲ 0% | -7.35M▼ 6519.8% | -605K▲ 91.8% | 20.1M▲ 3422.3% | 0▼ 100.0% | 151K▲ 0% | 3.55M▲ 2251.0% | 242.55M▲ 6732.5% | 32.01M▲ 0% |
Gross Margin % | -1.11% | -73.48% | - | 100% | - | 100% | 100% | 99.38% | 96.48% |
Gross Profit Growth % | - | -6519.82% | 91.77% | 3422.31% | -100% | - | 2250.99% | 6732.45% | - |
Operating Expenses | 11.32M | 20M | 46.05M | 76.47M | 114.79M | 170.09M | 214.38M | 171.93M | 142.36M |
OpEx % of Revenue | 113.21% | 200.05% | - | 380.46% | - | 112643.71% | 6038.96% | 70.45% | - |
Selling, General & Admin | 1.58M | 3.18M | 12.19M | 21.33M | 27.52M | 34.83M | 40.75M | 46.85M | 46.5M |
SG&A % of Revenue | 15.8% | 31.84% | - | 106.12% | - | 23068.87% | 1148% | 19.2% | - |
Research & Development | 10.11M | 17.38M | 33.86M | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M | 97.03M |
R&D % of Revenue | 101.11% | 173.79% | - | 274.34% | - | 89574.83% | 4890.96% | 53.12% | - |
Other Operating Expenses | 237K | -558K | 0 | 0 | 0 | 0 | 0 | -4.56M | -1.17M |
Operating Income | -1.69M▲ 0% | -10.56M▼ 524.7% | -46.66M▼ 341.7% | -56.37M▼ 20.8% | -114.79M▼ 103.6% | -169.94M▼ 48.0% | -210.83M▼ 24.1% | 70.62M▲ 133.5% | -110.35M▲ 0% |
Operating Margin % | -16.91% | -105.63% | - | -280.46% | - | -112543.71% | -5938.96% | 28.94% | -332.55% |
Operating Income Growth % | - | -524.66% | -341.7% | -20.82% | -103.63% | -48.05% | -24.06% | 133.5% | - |
EBITDA | -1.39M | -10.13M | -46.05M | -55.99M | -114.12M | -169.13M | -209.6M | 72.13M | -108.78M |
EBITDA Margin % | -13.87% | -101.25% | - | -278.58% | - | -112003.97% | -5904.34% | 29.55% | -327.83% |
EBITDA Growth % | - | -629.99% | -354.83% | -21.59% | -103.8% | -48.21% | -23.93% | 134.41% | -1106.79% |
D&A (Non-Cash Add-back) | 304K | 438K | 605K | 378K | 674K | 815K | 1.23M | 1.51M | 1.57M |
EBIT | -1.32M | -12.33M | -45.53M | -56.73M | -104.68M | -152.99M | -187.05M | 70.62M | -96.77M |
Net Interest Income | 6K | -8K | 0 | -4K | 0 | 0 | 0 | 0 | 0 |
Interest Income | 6K | 0 | 6K | 0 | 1K | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 8K | 6K | 4K | 1K | 0 | 0 | 0 | 0 |
Other Income/Expense | 613K | -1.77M | 1.12M | -360K | 10.11M | 16.95M | 23.78M | 21.27M | 20.04M |
Pretax Income | -1.08M▲ 0% | -12.34M▼ 1044.3% | -45.53M▼ 269.1% | -56.73M▼ 24.6% | -104.68M▼ 84.5% | -152.99M▼ 46.2% | -187.05M▼ 22.3% | 91.9M▲ 149.1% | -90.31M▲ 0% |
Pretax Margin % | -10.78% | -123.36% | - | -282.25% | - | -101319.21% | -5269.1% | 37.65% | -272.15% |
Income Tax | 257K | 0 | -172K | 2.01M | 0 | 0 | 300K | 4.88M | -5.16M |
Effective Tax Rate % | -23.84% | 0% | 0.38% | -3.54% | 0% | 0% | -0.16% | 5.31% | 5.71% |
Net Income | -1.33M▲ 0% | -12.34M▼ 824.6% | -45.36M▼ 267.5% | -58.74M▼ 29.5% | -104.68M▼ 78.2% | -152.99M▼ 46.2% | -187.35M▼ 22.5% | 87.01M▲ 146.4% | -85.14M▲ 0% |
Net Margin % | -13.35% | -123.44% | - | -292.26% | - | -101319.21% | -5277.55% | 35.65% | -256.6% |
Net Income Growth % | - | -824.64% | -267.47% | -29.5% | -78.2% | -46.15% | -22.46% | 146.44% | -2121.49% |
Net Income (Continuing) | -1.33M | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M | -187.35M | 87.01M | -85.14M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.15▲ 0% | -1.39▼ 826.7% | -2.93▼ 110.8% | -2.52▲ 14.0% | -4.15▼ 64.7% | -5.20▼ 25.3% | -5.00▲ 3.8% | 2.30▲ 146.0% | -2.25▲ 0% |
EPS Growth % | - | -826.67% | -110.79% | 13.99% | -64.68% | -25.3% | 3.85% | 146% | -712.5% |
EPS (Basic) | -0.15 | -1.39 | -2.93 | -2.52 | -4.15 | -5.20 | -5.00 | 2.34 | - |
Diluted Shares Outstanding | 8.88M | 8.88M | 15.51M | 23.33M | 25.24M | 29.45M | 37.44M | 37.86M | 37.86M |
Basic Shares Outstanding | 8.88M | 8.88M | 15.51M | 23.33M | 25.24M | 29.45M | 37.44M | 37.22M | 37.22M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KROS Balance Sheet
Keros Therapeutics, Inc. (KROS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25.53M | 8.93M | 267.73M | 251.44M | 285.77M | 347.29M | 588.89M | 315.43M | 290.68M |
Cash & Short-Term Investments | 23.26M | 7.02M | 265.88M | 230.04M | 279.05M | 331.15M | 559.93M | 287.42M | 281.5M |
Cash Only | 23.26M | 7.02M | 265.88M | 230.04M | 279.05M | 331.15M | 559.93M | 287.42M | 281.5M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 922K | 216K | 18.2M | 841K | 1.09M | 4.46M | 6.37M | 2.65M |
Days Sales Outstanding | - | 33.65 | - | 330.44 | - | 2.64K | 458.15 | 9.53 | 88.9 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 84K | 819K | 160K | 210K | 276K | 1M | 1.48M | 21.65M | 6.53M |
Total Non-Current Assets | 1.88M | 2.03M | 1.72M | 3.81M | 21.01M | 22.73M | 26.99M | 22.59M | 21.62M |
Property, Plant & Equipment | 1.38M | 1.91M | 1.6M | 2.4M | 17.57M | 19.47M | 23.49M | 21.14M | 20.17M |
Fixed Asset Turnover | 7.25x | 5.23x | - | 8.37x | - | 0.01x | 0.15x | 11.55x | 1.54x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 501K | 0 | 0 | 0 | 0 | 1.21M | 1.45M | 1.45M | 2.9M |
Other Non-Current Assets | 0 | 115K | 115K | 1.41M | 3.44M | 2.05M | 2.06M | 0 | 1.45M |
Total Assets | 27.41M▲ 0% | 10.96M▼ 60.0% | 269.44M▲ 2359.5% | 255.25M▼ 5.3% | 306.78M▲ 20.2% | 370.02M▲ 20.6% | 615.89M▲ 66.4% | 338.02M▼ 45.1% | 312.29M▲ 0% |
Asset Turnover | 0.36x | 0.91x | - | 0.08x | - | 0.00x | 0.01x | 0.72x | 0.06x |
Asset Growth % | - | -60.04% | 2359.54% | -5.27% | 20.19% | 20.62% | 66.44% | -45.12% | -10.68% |
Total Current Liabilities | 11.47M | 4.49M | 7.18M | 11.85M | 16.55M | 24.37M | 27.45M | 20.41M | 12.85M |
Accounts Payable | 501K | 2.09M | 2.15M | 3.65M | 3.34M | 5.45M | 4.6M | 1.97M | 1.49M |
Days Payables Outstanding | 18.09 | 43.93 | 1.3K | - | - | - | - | 475.78 | 861.33 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.41M | 2.5M |
Deferred Revenue (Current) | 10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.08M |
Other Current Liabilities | 477K | 1.02M | 1.73M | 2.58M | 5.56M | 10.38M | 10.55M | 16.04M | 8.86M |
Current Ratio | 2.23x | 1.99x | 37.27x | 21.23x | 17.27x | 14.25x | 21.45x | 15.45x | 22.62x |
Quick Ratio | 2.23x | 1.99x | 37.27x | 21.23x | 17.27x | 14.25x | 21.45x | 15.45x | 22.62x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -772.43 |
Total Non-Current Liabilities | 3.19M | 5.97M | 538K | 231K | 12.81M | 13.44M | 16.88M | 14.47M | 13.81M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.81M |
Capital Lease Obligations | 622K | 899K | 476K | 231K | 12.81M | 13.44M | 16.88M | 14.47M | 45.31M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2.56M | 5.08M | 62K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.65M | 10.46M | 7.72M | 12.08M | 29.36M | 37.81M | 44.33M | 34.89M | 26.66M |
Total Debt | 788K | 1.27M | 899K | 1.09M | 13.27M | 14.44M | 18.86M | 16.88M | 16.31M |
Net Debt | -22.47M | -5.75M | -264.98M | -228.95M | -265.78M | -316.7M | -541.07M | -270.53M | -265.19M |
Debt / Equity | 0.06x | 2.58x | 0.00x | 0.00x | 0.05x | 0.04x | 0.03x | 0.06x | 0.06x |
Debt / EBITDA | - | - | - | - | - | - | - | 0.23x | -0.15x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -3.75x | 2.44x |
Interest Coverage | - | -1541.00x | -7587.83x | -14182.25x | -104678.00x | - | - | - | - |
Total Equity | 12.76M▲ 0% | 495K▼ 96.1% | 261.72M▲ 52772.9% | 243.17M▼ 7.1% | 277.42M▲ 14.1% | 332.21M▲ 19.7% | 571.55M▲ 72.0% | 303.13M▼ 47.0% | 285.63M▲ 0% |
Equity Growth % | - | -96.12% | 52772.93% | -7.09% | 14.08% | 19.75% | 72.04% | -46.96% | -7.83% |
Book Value per Share | 1.44 | 0.06 | 16.88 | 10.42 | 10.99 | 11.28 | 15.27 | 8.01 | 7.54 |
Total Shareholders' Equity | 12.76M | 495K | 261.72M | 243.17M | 277.42M | 332.21M | 571.55M | 303.13M | 285.63M |
Common Stock | 1K | 1K | 2K | 2K | 2K | 3K | 4K | 4K | 4K |
Retained Earnings | -7.31M | -19.65M | -65.01M | -123.75M | -228.43M | -381.43M | -568.78M | -481.76M | -505.47M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -384.56M | 0 |
Accumulated OCI | -246K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KROS Cash Flow Statement
Keros Therapeutics, Inc. (KROS) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 7.04M | -16M | -36.89M | -62.15M | -70.06M | -124.51M | -160.87M | 107.5M | -57.2M |
Operating CF Margin % | 70.42% | -159.98% | - | -309.19% | - | -82455.63% | -4531.52% | 44.05% | - |
Operating CF Growth % | - | -327.18% | -130.62% | -68.45% | -12.73% | -77.71% | -29.2% | 166.83% | 74.72% |
Net Income | -1.33M | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M | -187.35M | 87.01M | -85.14M |
Depreciation & Amortization | 153K | 438K | 278K | 378K | 674K | 815K | 1.23M | 1.51M | 1.57M |
Stock-Based Compensation | 81K | 0 | 4.1M | 11.72M | 18.68M | 28.76M | 34.87M | 28.7M | 19.83M |
Deferred Taxes | 0 | 0 | 0 | 46K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 194K | 2.62M | 1.82M | 520K | 953K | 1.56M | 1.82M | 2.4M | 8.65M |
Working Capital Changes | 7.95M | -6.72M | 2.27M | -16.07M | 14.31M | -2.65M | -11.44M | -12.11M | -2.1M |
Change in Receivables | -370K | -552K | 922K | -18M | 18M | -143K | -2.6M | -825K | 14.64M |
Change in Inventory | 0 | 0 | -922K | 1.04M | 0 | -4.5M | 0 | 0 | 0 |
Change in Payables | -2K | 1.31M | 61K | 1.49M | -408K | 1.61M | -249K | -3M | -5.13M |
Cash from Investing | -217K | -271K | -294K | -1.02M | -1.24M | -2.46M | -1.93M | -1.55M | -1.06M |
Capital Expenditures | -217K | -271K | -294K | -1.02M | -1.24M | -2.46M | -1.93M | -1.55M | -1.06M |
CapEx % of Revenue | 2.17% | 2.71% | - | 5.09% | - | 1631.79% | 54.39% | 0.64% | 3.19% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 11.46M | 14K | 296.04M | 28.55M | 120.31M | 178.96M | 391.82M | -378.47M | -380.79M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 11.5M | 14K | 299.2M | 28.17M | 119.58M | 175.82M | 380.13M | -378.47M | 289K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -375M | 0 |
Other Financing | -37K | 0 | -3.16M | 379K | 731K | 3.13M | 11.69M | 0 | -381.08M |
Net Change in Cash | 18.29M▲ 0% | -16.24M▼ 188.8% | 258.86M▲ 1694.0% | -34.62M▼ 113.4% | 49.01M▲ 241.5% | 51.98M▲ 6.1% | 229.02M▲ 340.6% | -272.52M▼ 219.0% | -439.04M▲ 0% |
Free Cash Flow | 6.83M▲ 0% | -16.27M▼ 338.4% | -37.19M▼ 128.6% | -63.17M▼ 69.9% | -71.3M▼ 12.9% | -126.97M▼ 78.1% | -162.8M▼ 28.2% | 105.95M▲ 165.1% | -58.25M▲ 0% |
FCF Margin % | 68.25% | -162.69% | - | -314.29% | - | -84087.42% | -4585.92% | 43.41% | -175.56% |
FCF Growth % | - | -338.37% | -128.58% | -69.87% | -12.87% | -78.07% | -28.22% | 165.08% | -234.5% |
FCF per Share | 0.77 | -1.83 | -2.40 | -2.71 | -2.82 | -4.31 | -4.35 | 2.80 | -1.54 |
FCF Conversion (FCF/Net Income) | -5.27x | 1.30x | 0.81x | 1.06x | 0.67x | 0.81x | 0.86x | 1.24x | 0.68x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.64M |
KROS Key Ratios
Keros Therapeutics, Inc. (KROS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -186.28% | -34.6% | -23.27% | -40.22% | -50.19% | -41.46% | 19.9% | -17.04% |
Return on Invested Capital (ROIC) | - | - | -770.9% | -665.68% | -938.87% | -687.6% | 167.93% | -287.73% |
Gross Margin | -73.48% | - | 100% | - | 100% | 100% | 99.38% | 96.48% |
Net Margin | -123.44% | - | -292.26% | - | -101319.21% | -5277.55% | 35.65% | -256.6% |
Debt / Equity | 2.58x | 0.00x | 0.00x | 0.05x | 0.04x | 0.03x | 0.06x | 0.06x |
Interest Coverage | -1541.00x | -7587.83x | -14182.25x | -104678.00x | - | - | - | - |
FCF Conversion | 1.30x | 0.81x | 1.06x | 0.67x | 0.81x | 0.86x | 1.24x | 0.68x |
Revenue Growth | 0% | -100% | - | -100% | - | 2250.99% | 6774.96% | -84.55% |
Related:KROS Dividend History·KROS Revenue History·KROS Price History·KROS P/E History·KROS Financial Ratios·KROS Institutional Holders
KROS SEC Filings & Documents
Keros Therapeutics, Inc. (KROS) SEC filings — annual & quarterly reports (10-K, 10-Q)
KROS Frequently Asked Questions
Keros Therapeutics, Inc. (KROS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Keros Therapeutics, Inc. (KROS) reported $33.2M in revenue for fiscal year 2025. This represents a 232% increase from $10.0M in 2018.
Keros Therapeutics, Inc. (KROS) grew revenue by 6775.0% over the past year. This is strong growth.
Keros Therapeutics, Inc. (KROS) reported a net loss of $85.1M for fiscal year 2025.
Dividend & Returns
Keros Therapeutics, Inc. (KROS) has a return on equity (ROE) of 19.9%. This is reasonable for most industries.
Keros Therapeutics, Inc. (KROS) had negative free cash flow of $58.3M in fiscal year 2025, likely due to heavy capital investments.